Macquarie Group’s Zimmer Biomet ZBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.22M Sell
13,488
-21,733
-62% -$1.99M 0.01% 612
2025
Q4
$3.17M Sell
35,221
-436,031
-93% -$41.3M 0.01% 497
2025
Q3
$44.6M Buy
471,252
+224,745
+91% +$22.3M 0.05% 455
2025
Q2
$22.5M Sell
246,507
-2,860
-1% -$277K 0.03% 636
2025
Q1
$28.2M Buy
249,367
+9,851
+4% +$1.05M 0.04% 561
2024
Q4
$24.5M Sell
239,516
-8,988
-4% -$964K 0.03% 606
2024
Q3
$26.8M Sell
248,504
-10,351
-4% -$1.13M 0.03% 609
2024
Q2
$28.1M Buy
258,855
+17,654
+7% +$2.08M 0.03% 578
2024
Q1
$31.8M Sell
241,201
-240
-0.1% -$30K 0.04% 570
2023
Q4
$29.4M Buy
241,441
+3,724
+2% +$416K 0.03% 587
2023
Q3
$26.7M Sell
237,717
-2,552
-1% -$324K 0.03% 576
2023
Q2
$35M Sell
240,269
-1,277
-0.5% -$174K 0.04% 539
2023
Q1
$31.2M Sell
241,546
-272,159
-53% -$34.2M 0.04% 562
2022
Q4
$65.5M Sell
513,705
-13,559
-3% -$1.57M 0.08% 351
2022
Q3
$55.1M Sell
527,264
-25,733
-5% -$2.82M 0.07% 392
2022
Q2
$58.1M Buy
552,997
+11,175
+2% +$1.33M 0.07% 397
2022
Q1
$69.3K Buy
541,822
+79,809
+17% +$9.62M 0.05% 410
2021
Q4
$57M Sell
462,013
-1,611,137
-78% -$211M 0.05% 478
2021
Q3
$295M Buy
2,073,150
+13,320
+0.6% +$1.96M 0.25% 81
2021
Q2
$322M Buy
2,059,830
+1,818,718
+754% +$295M 0.26% 83
2021
Q1
$37.5M Sell
241,112
-5,974
-2% -$925K 0.05% 395
2020
Q4
$37M Sell
247,086
-13,081
-5% -$1.85M 0.05% 376
2020
Q3
$34.4M Sell
260,167
-11,308
-4% -$1.48M 0.06% 344
2020
Q2
$31.5M Sell
271,475
-3,484
-1% -$401K 0.05% 364
2020
Q1
$27M Sell
274,959
-29,458
-10% -$3.86M 0.06% 343
2019
Q4
$44.2M Buy
304,417
+138,535
+84% +$19.1M 0.06% 327
2019
Q3
$22.1M Sell
165,882
-9,630
-5% -$1.24M 0.04% 429
2019
Q2
$20.1M Sell
175,512
-10,249
-6% -$1.2M 0.03% 460
2019
Q1
$23M Sell
185,761
-49,440
-21% -$5.62M 0.04% 424
2018
Q4
$23.7M Buy
235,201
+979
+0.4% +$110K 0.05% 387
2018
Q3
$29.9M Buy
234,222
+669
+0.3% +$79.5K 0.05% 383
2018
Q2
$25.3M Buy
233,553
+11,536
+5% +$1.26M 0.04% 430
2018
Q1
$23.5M Buy
222,017
+102,073
+85% +$11.9M 0.04% 423
2017
Q4
$14.4M Sell
119,944
-412
-0.3% -$46.6K 0.03% 550
2017
Q3
$13.7M Sell
120,356
-3,379
-3% -$390K 0.02% 546
2017
Q2
$15.4M Sell
123,735
-4,645
-4% -$551K 0.03% 510
2017
Q1
$15.2M Buy
128,380
+3,492
+3% +$396K 0.03% 518
2016
Q4
$12.5M Sell
124,888
-360
-0.3% -$38.6K 0.02% 556
2016
Q3
$15.8M Sell
125,248
-125,454
-50% -$15.5M 0.03% 489
2016
Q2
$29.3M Buy
250,702
+125,711
+101% +$14.2M 0.03% 469
2016
Q1
$12.9M Sell
124,991
-206
-0.2% -$19.9K 0.03% 473
2015
Q4
$12.5M Buy
125,197
+7,159
+6% +$700K 0.03% 480
2015
Q3
$10.8M Buy
118,038
+18,437
+19% +$1.85M 0.02% 502
2015
Q2
$10.6M Buy
99,601
+51
+0.1% +$5.64K 0.02% 528
2015
Q1
$11.4M Hold
99,550
0.02% 515
2014
Q4
$11M Buy
99,550
+3,605
+4% +$380K 0.02% 500
2014
Q3
$9.37M Buy
95,945
+12,927
+16% +$1.27M 0.02% 522
2014
Q2
$8.37M Buy
83,018
+24,514
+42% +$2.39M 0.02% 549
2014
Q1
$5.37M Sell
58,504
-10,712
-15% -$987K 0.01% 650
2013
Q4
$6.26M Buy
69,216
+25,716
+59% +$2.23M 0.01% 580
2013
Q3
$3.47M Buy
43,500
+2,712
+7% +$213K 0.01% 715
2013
Q2
$2.97M Buy
+40,788
New +$3.05M 0.01% 736

Other funds holding ZBH

Macquarie Group's ZBH Position: Q1 2026 in Review

Macquarie Group reduced its Zimmer Biomet (ZBH) stake by 62% in Q1 2026, selling an estimated $1.99M and leaving 13,488 shares worth $1.22M. The position accounts for 0.01% of the portfolio, ranked #612.

Macquarie Group first reported a position in ZBH in Q2 2013 and has held it in 52 quarters since. The position peaked at $322M in Q2 2021. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.

  • Macquarie Group held 13,488 shares of Zimmer Biomet worth $1.22M as of Q1 2026.
  • Macquarie Group sold 21,733 Zimmer Biomet shares in Q1 2026, an estimated $1.99M.
  • Zimmer Biomet made up 0.01% of Macquarie Group's portfolio in Q1 2026, its #612 holding.
  • Macquarie Group first reported a position in Zimmer Biomet in Q2 2013 and has held it in 52 quarters since.
  • Macquarie Group's Zimmer Biomet position peaked at $322M in Q2 2021.
  • 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.

Based on Macquarie Group's 13F filing for Q1 2026, filed 15 May 2026.